PRECIGEN, INC. Total Assets
PRECIGEN, INC. (PGEN) had Total Assets of $170.30 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Assets
us-gaap:Assets · last filed 2026-08-04
- 2026-06-30: Assets $170.30M.
- 2026-03-31: Assets $138.63M.
- 2025-12-31: Assets $155.50M.
- 2025-09-30: Assets $171.26M.
| Period end | Assets |
|---|---|
| 2026-06-30 | $170.30M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $138.63M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $155.50M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $171.26M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $101.90M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $128.79M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $145.27M 10-K · filed 2026-03-25 |
| 2024-09-30 | $83.47M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $73.16M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $134.85M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $151.04M 10-K · filed 2025-03-19 |
| 2023-09-30 | $190.69M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $207.53M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $241.55M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $215.98M 10-K · filed 2024-03-19 |
| 2022-09-30 | $259.25M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $321.22M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $335.57M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $359.86M 10-K · filed 2023-03-06 |
| 2021-09-30 | $376.90M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $402.57M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $406.98M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $314.59M 10-K · filed 2022-03-01 |
| 2020-09-30 | $336.19M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $361.71M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $404.67M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $455.76M 10-K · filed 2021-03-01 |
| 2019-09-30 | $604.90M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $655.19M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $709.86M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $716.18M 10-K · filed 2020-03-02 |
| 2018-09-30 | $980.41M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $825.15M 10-Q · filed 2018-08-13 |
| 2018-03-31 | $895.67M 10-Q/A · filed 2018-08-13 |
| 2017-12-31 | $846.85M 10-K · filed 2019-03-01 |
| 2017-09-30 | $898.26M 10-Q · filed 2017-11-09 |
| 2017-06-30 | $933.99M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $915.93M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $949.07M 10-K · filed 2018-03-01 |
| 2016-09-30 | $1.01B 10-Q · filed 2016-11-09 |
| 2016-06-30 | $1.03B 10-Q · filed 2016-08-09 |
| 2016-03-31 | $962.43M 10-Q · filed 2016-05-10 |
| 2015-12-31 | $982.05M 10-K · filed 2017-03-01 |
| 2015-09-30 | $989.89M 10-Q · filed 2015-11-09 |
| 2015-06-30 | $792.94M 10-Q · filed 2015-08-10 |
| 2015-03-31 | $819.99M 10-Q · filed 2015-05-11 |
| 2014-12-31 | $576.27M 10-K · filed 2016-02-29 |
| 2014-09-30 | $538.50M 10-Q · filed 2014-11-13 |
| 2014-06-30 | $500.54M 10-Q · filed 2014-08-14 |
| 2014-03-31 | $547.81M 10-Q · filed 2014-05-09 |
| 2013-12-31 | $469.47M 10-K · filed 2015-03-02 |
| 2013-09-30 | $474.20M 10-Q · filed 2013-11-07 |
| 2013-06-30 | $283.45M 10-Q/A · filed 2013-10-21 |
| 2012-12-31 | $151.65M 10-K · filed 2014-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |